Fintel reports that on April 24, 2023, Barclays upgraded their outlook for Medtronic (NYSE:MDT) from Equal-Weight to Overweight .
Analyst Price Forecast Suggests 5.57% Upside
As of April 6, 2023, the average one-year price target for Medtronic is 90.50. The forecasts range from a low of 77.77 to a high of $105.00. The average price target represents an increase of 5.57% from its latest reported closing price of 85.73.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Medtronic is 30,781MM, an increase of 0.03%. The projected annual non-GAAP EPS is 5.32.
Medtronic Declares $0.68 Dividend
On March 2, 2023 the company declared a regular quarterly dividend of $0.68 per share ($2.72 annualized). Shareholders of record as of March 24, 2023 received the payment on April 14, 2023. Previously, the company paid $0.68 per share.
At the current share price of $85.73 / share, the stock's dividend yield is 3.17%.
Looking back five years and taking a sample every week, the average dividend yield has been 2.32%, the lowest has been 1.77%, and the highest has been 3.57%. The standard deviation of yields is 0.44 (n=237).
The current dividend yield is 1.94 standard deviations above the historical average.
Additionally, the company's dividend payout ratio is 0.89. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.
The company's 3-Year dividend growth rate is 0.26%, demonstrating that it has increased its dividend over time.
What is the Fund Sentiment?
There are 3201 funds or institutions reporting positions in Medtronic. This is an increase of 39 owner(s) or 1.23% in the last quarter. Average portfolio weight of all funds dedicated to MDT is 0.59%, an increase of 7.79%. Total shares owned by institutions decreased in the last three months by 0.12% to 1,261,710K shares. 
The put/call ratio of MDT is 0.82, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 40,441K shares representing 3.04% ownership of the company. In it's prior filing, the firm reported owning 39,665K shares, representing an increase of 1.92%. The firm decreased its portfolio allocation in MDT by 9.38% over the last quarter.
Massachusetts Financial Services holds 35,400K shares representing 2.66% ownership of the company. No change in the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 30,726K shares representing 2.31% ownership of the company. In it's prior filing, the firm reported owning 30,120K shares, representing an increase of 1.97%. The firm decreased its portfolio allocation in MDT by 9.55% over the last quarter.
Wellington Management Group Llp holds 29,857K shares representing 2.24% ownership of the company. No change in the last quarter.
Capital Research Global Investors holds 28,815K shares representing 2.17% ownership of the company. In it's prior filing, the firm reported owning 28,777K shares, representing an increase of 0.13%. The firm decreased its portfolio allocation in MDT by 11.35% over the last quarter.
Medtronic Background Information
(This description is provided by the company.)
Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
See all Medtronic regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
